Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine
et al., Journal of Medical Virology, doi:10.1002/jmv.27731
, Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with.., Journal of Medical Virology, doi:10.1002/jmv.27731
Retrospective 317 HCQ users and 333 household contacts, showing higher risk with HCQ.Authors do not adjust for the very different baseline risk for systemic
autoimmune disease patients. Other research shows that the risk of COVID-19
for systemic autoimmune disease patients is much higher overall, Ferri et al.
show OR 4.42, p<0.001 [Ferri].
This study is excluded in the after exclusion results of meta
analysis:
not adjusting for the different baseline risk of systemic autoimmune patients; excessive unadjusted differences between groups.
|
risk of hospitalization, 215.1% higher, RR 3.15, p = 0.36, treatment 3 of 317 (0.9%), control 1 of 333 (0.3%).
|
|
risk of symptomatic case, 40.1% higher, RR 1.40, p = 0.44, treatment 16 of 317 (5.0%), control 12 of 333 (3.6%).
|
|
risk of case, 5.0% higher, RR 1.05, p = 0.88, treatment 22 of 317 (6.9%), control 22 of 333 (6.6%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Oztas et al., 21 Mar 2022, retrospective, Turkey, peer-reviewed, 15 authors.
Abstract: Sarvan Aghamuradov ORCID iD: 0000-0002-7196-0098
Serdal Ugurlu ORCID iD: 0000-0002-9561-2282
Frequency and Severity of COVID-19 in Patients with Various Rheumatic
Diseases Treated Regularly with Colchicine or Hydroxychloroquine
Mert Oztas1(Orcid ID: 0000-0002-4077-1374), Murat Bektas2(Orcid ID: 0000-0002-
Accepted Article
1788-3837), Ilker Karacan3 (Orcid ID: 0000-0003-3100-0866), Numune
Aliyeva2(Orcid ID: 0000-0003-2848-4396), Ayten Dag1 (Orcid ID: 0000-0003-3157531X), Sarvan Aghamuradov2(Orcid ID: 0000-0002-7196-0098), Selim Berke
Cevirgen1 (Orcid ID: 0000-0002-7099-4827), Selma Sari2 (Orcid ID: 0000-00016839-8164), Murat Bolayirli4 (Orcid ID: 0000-0001-5755-7860),Gunay Can5 (00000001-5815-6700), Gulen Hatemi1 (0000-0002-1952-1135), Emire Seyahi1 (00000003-4965-2918),Huri Ozdogan1 (Orcid ID: 0000-0003-4632-8258), Ahmet Gul2
(Orcid ID: 0000-0001-8219-3720), Serdal Ugurlu1 (Orcid ID: 0000-0002-9561-2282)
1- Istanbul University-Cerrahpasa, Department of Medicine, Division of
Rheumatology, Istanbul, Turkey
2- Istanbul University, Department of Medicine, Division of Rheumatology,
Istanbul, Turkey
3- Istanbul Medeniyet University,Department of Molecular Biology and
Genetics, Istanbul, Turkey
4- Istanbul University-Cerrahpasa, Department of Medical Biochemistry,
Istanbul, Turkey
5- Istanbul University-Cerrahpasa, Department of Public Health, Istanbul, Turkey
Corresponding Author:
Serdal Ugurlu (MD) Rheumatology Department, Istanbul University Cerrahpasa,
Istanbul, Turkey
Cell Phone no: 02124143000
E-mail: serdalugurlu@gmail.com
Word Count: 1535
Declarations
Funding This study was supported by Department of Scientific Research
Projects,Istanbul University-Cerrahpasa (Grant number:34919)
Conflict of Intersest Statement No conflict of interest declared
Ethics approval This study was approved by Istanbul University-Cerrahpasa Ethics
Comitee (14.05.2020-62050).
This article has been accepted for publication and undergone full peer review but has
not been through the copyediting, typesetting, pagination and proofreading process,
which may lead to differences between this version and the Version of Record. Please
cite this article as doi: 10.1002/jmv.27731.
This article is protected by copyright. All rights reserved.
Accepted Article
All authors were involved in drafting the article or revising it, and all authors
approved the final version to be published. Dr. Ugurlu had full access to all of the data
in the
study and takes responsibility for the integrity of the data and the accuracy of the data
analysis.
Study conception and design.
Mert Oztas, Murat Bektas, Ilker Karacan, Numune Aliyeva, Ayten Dag, Sarvan
Aghamuradov, Selim Berke Cevirgen, Selma Sari, Murat Bolayirli, Gunay Can, Huri
Ozdogan, Ahmet Gul, Serdal Ugurlu
Acquisition of data. Mert Oztas, Murat Bektas, Numune Aliyeva, Ayten Dag, Sarvan
Aghamuradov, Selim Berke Cevirgen, Selma Sari, Murat Bolayirli
Analysis and interpretation of data. Mert Oztas, Murat Bektas Gunay Can,, Huri
Ozdogan, Ahmet Gul, Serdal Ugurlu
Data Availability Statement The data that support the findings of this study are
available on request from the corresponding author. The data are not publicly
available due to privacy or ethical restrictions.
Consent for Publication We hereby confirm that this article has not been published
and is not under consideration for publication elsewhere. All authors have contributed
to, seen, and approved the final, submitted version of the manuscript.
Consent to Participate Written..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.